PMID- 10997745
OWN - NLM
STAT- MEDLINE
DCOM- 20010109
LR  - 20151119
IS  - 1071-9164 (Print)
IS  - 1071-9164 (Linking)
VI  - 6
IP  - 3
DP  - 2000 Sep
TI  - Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, 
      and brain natriuretic peptide as prognostic markers of survival in congestive 
      heart failure.
PG  - 201-7
AB  - BACKGROUND: Endothelin-1 (ET-1) and cardiac natriuretic peptide plasma 
      concentrations have prognostic significance in congestive heart failure (CHF). 
      However, their respective prognostic values in this setting have never been 
      directly compared. METHODS AND RESULTS: We studied the prognostic performances of 
      ET-1, N-terminal proatrial natriuretic factor (N-proANF), and brain natriuretic 
      peptide (BNP) to predict the long-term cardiac mortality in fully treated 
      patients with CHF. Peripheral plasma concentrations of the 3 peptides were 
      measured in 109 patients (left ventricular ejection fraction [LVEF] < 35%) in New 
      York Heart Association (NYHA) functional classes II (n = 65) or III to IV (n = 
      44). The outcome of the patients was evaluated 3 years after the beginning of the 
      study, and a Cox regression model was used to identify predictors of death. 
      Plasma concentrations of the 3 peptides increased with the severity of heart 
      failure. By univariate analysis, 6 parameters were significantly associated with 
      death during follow-up: ET-1 level, NYHA classes III to IV, N-proANF level, BNP 
      level, LVEF, and age (all P < .01). By multivariate analysis, only ET-1 level 
      and, to a lesser extent, N-proANF level contributed significantly and 
      independently to risk stratification (chi2 = 53.4 and 12.8; P < .0001 and P < 
      .001, respectively). CONCLUSION: In a group of patients in whom the vast majority 
      were administered angiotensin-converting enzyme inhibitor therapy, plasma ET-1 
      and N-proANF concentrations identify better than several clinical markers a very 
      high-risk group, fairly amenable to heart transplantation or new therapies.
FAU - Selvais, P L
AU  - Selvais PL
AD  - Diabetes and Nutrition Unit, University of Louvain, Brussels, Belgium.
FAU - Robert, A
AU  - Robert A
FAU - Ahn, S
AU  - Ahn S
FAU - van Linden, F
AU  - van Linden F
FAU - Ketelslegers, J M
AU  - Ketelslegers JM
FAU - Pouleur, H
AU  - Pouleur H
FAU - Rousseau, M F
AU  - Rousseau MF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
RN  - 0 (Biomarkers)
RN  - 0 (Endothelin-1)
RN  - 0 (Protein Precursors)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Aged
MH  - Atrial Natriuretic Factor/*blood
MH  - Belgium/epidemiology
MH  - Biomarkers/blood
MH  - Endothelin-1/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Protein Precursors/*blood
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2000/09/21 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/21 11:00
PHST- 2000/09/21 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/21 11:00 [entrez]
AID - S1071-9164(00)61771-2 [pii]
AID - 10.1054/jcaf.2000.8833 [doi]
PST - ppublish
SO  - J Card Fail. 2000 Sep;6(3):201-7. doi: 10.1054/jcaf.2000.8833.